Chaperome Networks - Redundancy and Implications for Cancer Treatment
Overview
General Medicine
Affiliations
The chaperome is a large family of proteins composed of chaperones, co-chaperones and a multitude of other factors. Elegant studies in yeast and other organisms have paved the road to how we currently understand the complex organization of this large family into protein networks. The goal of this chapter is to provide an overview of chaperome networks in cancer cells, with a focus on two cellular states defined by chaperome network organization. One state characterized by chaperome networks working in isolation and with little overlap, contains global chaperome networks resembling those of normal, non-transformed, cells. We propose that in this state, redundancy in chaperome networks results in a tumor type unamenable for single-agent chaperome therapy. The second state comprises chaperome networks interconnected in response to cellular stress, such as MYC hyperactivation. This is a state where no redundant pathways can be deployed, and is a state of vulnerability, amenable for chaperome therapy. We conclude by proposing a change in how we discover and implement chaperome inhibitor strategies, and suggest an approach to chaperome therapy where the properties of chaperome networks, rather than genetics or client proteins, are used in chaperome inhibitor implementation.
Tracing genetic diversity captures the molecular basis of misfolding disease.
Zhao P, Wang C, Sun S, Wang X, Balch W Nat Commun. 2024; 15(1):3333.
PMID: 38637533 PMC: 11026414. DOI: 10.1038/s41467-024-47520-0.
Regulation of Epithelial and Endothelial Barriers by Molecular Chaperones.
Lechuga S, Marino-Melendez A, Naydenov N, Zafar A, Braga-Neto M, Ivanov A Cells. 2024; 13(5.
PMID: 38474334 PMC: 10931179. DOI: 10.3390/cells13050370.
The dance of proteostasis and metabolism: Unveiling the caloristatic controlling switch.
Schroeder H, de Lemos Muller C, Heck T, Krause M, Homem de Bittencourt Jr P Cell Stress Chaperones. 2024; 29(1):175-200.
PMID: 38331164 PMC: 10939077. DOI: 10.1016/j.cstres.2024.02.002.
Maiti S, Bhattacharya K, Wider D, Hany D, Panasenko O, Bernasconi L Elife. 2023; 12.
PMID: 38059913 PMC: 10703448. DOI: 10.7554/eLife.88658.
How aberrant N-glycosylation can alter protein functionality and ligand binding: An atomistic view.
Castelli M, Yan P, Rodina A, Digwal C, Panchal P, Chiosis G Structure. 2023; 31(8):987-1004.e8.
PMID: 37343552 PMC: 10526633. DOI: 10.1016/j.str.2023.05.017.